TGM2 and cranioectodermal dysplasia: TG2, being crucial for CeD pathogenesis, is a pertinent target for therapy, and this approach was recently tested in a phase 2, randomized, double-blind, placebo-controlled, dose-finding gluten challenge trial using the oral TG2 inhibitor ZED1227 (ref. 19).